Table of Contents Author Guidelines Submit a Manuscript
The Scientific World Journal
Volume 2014, Article ID 165461, 8 pages
http://dx.doi.org/10.1155/2014/165461
Review Article

Radiolabeled Probes Targeting Hypoxia-Inducible Factor-1-Active Tumor Microenvironments

1Department of Pharmaceutical Analytical Chemistry, Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama University, 1-1-1 Tsushima-naka, Kita-ku, Okayama 700-8530, Japan
2Department of Patho-Functional Bioanalysis, Graduate School of Pharmaceutical Sciences, Kyoto University, Kyoto 606-8501, Japan

Received 27 June 2014; Accepted 6 August 2014; Published 18 August 2014

Academic Editor: Takahiro Higuchi

Copyright © 2014 Masashi Ueda and Hideo Saji. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. J. M. Arbeit, J. M. Brown, K. S. C. Chao et al., “Hypoxia: importance in tumor biology, noninvasive measurement by imaging, and value of its measurement in the management of cancer therapy,” International Journal of Radiation Biology, vol. 82, no. 10, pp. 699–757, 2006. View at Publisher · View at Google Scholar · View at Scopus
  2. H. Rundqvist and R. S. Johnson, “Tumour oxygenation: Implications for breast cancer prognosis,” Journal of Internal Medicine, vol. 274, no. 2, pp. 105–112, 2013. View at Publisher · View at Google Scholar · View at Scopus
  3. M. R. Horsman, L. S. Mortensen, J. B. Petersen, M. Busk, and J. Overgaard, “Imaging hypoxia to improve radiotherapy outcome,” Nature Reviews Clinical Oncology, vol. 9, no. 12, pp. 674–687, 2012. View at Publisher · View at Google Scholar · View at Scopus
  4. Y. Yoo, M. Hayashi, J. Christensen, and L. E. Huang, “An essential role of the HIF-1α-c-Myc axis in malignant progression,” Annals of the New York Academy of Sciences, vol. 1177, pp. 198–204, 2009. View at Publisher · View at Google Scholar · View at Scopus
  5. D. M. Gilkes, G. L. Semenza, and D. Wirtz, “Hypoxia and the extracellular matrix: drivers of tumour metastasis,” Nature Reviews Cancer, vol. 14, no. 6, pp. 430–439, 2014. View at Publisher · View at Google Scholar
  6. G. L. Semenza, “HIF-1 mediates metabolic responses to intratumoral hypoxia and oncogenic mutations,” The Journal of Clinical Investigation, vol. 123, pp. 3664–3671, 2013. View at Google Scholar
  7. J. Pouysségur, F. Dayan, and N. M. Mazure, “Hypoxia signalling in cancer and approaches to enforce tumour regression,” Nature, vol. 441, no. 7092, pp. 437–443, 2006. View at Publisher · View at Google Scholar · View at Scopus
  8. G. L. Wang and G. L. Semenza, “Purification and characterization of hypoxia-inducible factor,” The Journal of Biological Chemistry, vol. 270, no. 3, pp. 1230–1237, 1995. View at Publisher · View at Google Scholar · View at Scopus
  9. D. P. Stiehl, W. Jelkmann, R. H. Wenger, and T. Hellwig-Bürgel, “Normoxic induction of the hypoxia-inducible factor 1α by insulin and interleukin-1β involves the phosphatidylinositol 3-kinase pathway,” FEBS Letters, vol. 512, no. 1–3, pp. 157–162, 2002. View at Publisher · View at Google Scholar · View at Scopus
  10. M. Pedersen, T. Löfstedt, J. Sun, L. Holmquist-Mengelbier, S. Påhlman, and L. Rönnstrand, “Stem cell factor induces HIF-1α at normoxia in hematopoietic cells,” Biochemical and Biophysical Research Communications, vol. 377, no. 1, pp. 98–103, 2008. View at Publisher · View at Google Scholar · View at Scopus
  11. S. Kizaka-Kondoh, S. Tanaka, H. Harada, and M. Hiraoka, “The HIF-1-active microenvironment: an environmental target for cancer therapy,” Advanced Drug Delivery Reviews, vol. 61, no. 7-8, pp. 623–632, 2009. View at Publisher · View at Google Scholar · View at Scopus
  12. M. Ivan, K. Kondo, H. Yang et al., “HIFα targeted for VHL-mediated destruction by proline hydroxylation: implications for O2 sensing,” Science, vol. 292, no. 5516, pp. 464–468, 2001. View at Publisher · View at Google Scholar · View at Scopus
  13. P. Jaakkola, D. R. Mole, Y. M. Tian et al., “Targeting of HIF-α to the von Hippel-Lindau ubiquitylation complex by O2-regulated prolyl hydroxylation,” Science, vol. 292, no. 5516, pp. 468–472, 2001. View at Google Scholar · View at Scopus
  14. N. Masson, C. Willam, P. H. Maxwell, C. W. Pugh, and P. J. Ratcliffe, “Independent function of two destruction domains in hypoxia-inducible factor-α chains activated by prolyl hydroxylation,” EMBO Journal, vol. 20, no. 18, pp. 5197–5206, 2001. View at Publisher · View at Google Scholar · View at Scopus
  15. F. Okumura, M. Matsuzaki, K. Nakatsukasa, and T. Kamura, “The role of Elongin BC-containing ubiquitin ligases,” Frontiers in Oncology, vol. 2, article 10, 2012. View at Google Scholar
  16. L. E. Huang, J. Gu, M. Schau, and H. F. Bunn, “Regulation of hypoxia-inducible factor 1α is mediated by an O2- dependent degradation domain via the ubiquitin-proteasome pathway,” Proceedings of the National Academy of Sciences of the United States of America, vol. 95, no. 14, pp. 7987–7992, 1998. View at Publisher · View at Google Scholar · View at Scopus
  17. P. H. Maxwell, M. S. Wlesener, G. W. Chang et al., “The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis,” Nature, vol. 399, no. 6733, pp. 271–275, 1999. View at Publisher · View at Google Scholar · View at Scopus
  18. S. M. Wood, J. M. Gleadle, C. W. Pugh, O. Hankinson, and P. J. Ratcliffe, “The role of the aryl hydrocarbon receptor nuclear translocator (ARNT) in hypoxic induction of gene expression: studies in ARNT-deficient cells,” The Journal of Biological Chemistry, vol. 271, no. 25, pp. 15117–15123, 1996. View at Publisher · View at Google Scholar · View at Scopus
  19. B. Jiang, E. Rue, G. L. Wang, R. Roe, and G. L. Semenza, “Dimerization, DNA binding, and transactivation properties of hypoxia- inducible factor 1,” Journal of Biological Chemistry, vol. 271, no. 30, pp. 17771–17778, 1996. View at Publisher · View at Google Scholar · View at Scopus
  20. B. H. Jiang, G. L. Semenza, C. Bauer, and H. H. Marti, “Hypoxia-inducible factor 1 levels vary exponentially over a physiologically relevant range of O2 tension,” The American Journal of Physiology—Cell Physiology, vol. 271, no. 4, pp. C1172–C1180, 1996. View at Google Scholar · View at Scopus
  21. D. M. Stroka, T. Burkhardt, I. Desbaillets et al., “HIF-1 is expressed in normoxic tissue and displays an organ-specific regulation under systemic hypoxia,” The FASEB Journal, vol. 15, no. 13, pp. 2445–2453, 2001. View at Google Scholar · View at Scopus
  22. K. L. Talks, H. Turley, K. C. Gatter et al., “The expression and distribution of the hypoxia-inducible factors HIF-1α and HIF-2α in normal human tissues, cancers, and tumor-associated macrophages,” American Journal of Pathology, vol. 157, no. 2, pp. 411–421, 2000. View at Publisher · View at Google Scholar · View at Scopus
  23. I. Serganova, M. Doubrovin, J. Vider et al., “Molecular imaging of temporal dynamics and spatial heterogeneity of hypoxia-inducible factor-1 signal transduction activity in tumors in living mice,” Cancer Research, vol. 64, no. 17, pp. 6101–6108, 2004. View at Publisher · View at Google Scholar · View at Scopus
  24. B. Wen, P. Burgman, P. Zanzonico et al., “A preclinical model for noninvasive imaging of hypoxia-induced gene expression; comparison with an exogenous marker of tumor hypoxia,” European Journal of Nuclear Medicine and Molecular Imaging, vol. 31, no. 11, pp. 1530–1538, 2004. View at Publisher · View at Google Scholar · View at Scopus
  25. S. Soghomonyan, A. Hajitou, R. Rangel et al., “Molecular PET imaging of HSV1-tk reporter gene expression using [18F]FEAU,” Nature Protocols, vol. 2, no. 2, pp. 416–423, 2007. View at Publisher · View at Google Scholar · View at Scopus
  26. S. S. Yaghoubi and S. S. Gambhir, “PET imaging of herpes simplex virus type 1 thymidine kinase (HSV1-tk) or mutant HSV1-sr39tk reporter gene expression in mice and humans using [18F]FHBG,” Nature Protocols, vol. 1, no. 6, pp. 3069–3075, 2007. View at Publisher · View at Google Scholar · View at Scopus
  27. I. Serganova and R. Blasberg, “Reporter gene imaging: potential impact on therapy,” Nuclear Medicine and Biology, vol. 32, no. 7, pp. 763–780, 2005. View at Publisher · View at Google Scholar · View at Scopus
  28. J. Y. Chan, J. Chung, H. K. Joo et al., “Visualization of hypoxia-inducible factor-1 transcriptional activation in C6 glioma using luciferase and sodium iodide symporter genes,” Journal of Nuclear Medicine, vol. 49, no. 9, pp. 1489–1497, 2008. View at Publisher · View at Google Scholar · View at Scopus
  29. S. Lehmann, E. G. Garayoa, A. Blanc, R. Keist, R. Schibli, and M. Rudin, “Recording intracellular molecular events from the outside: glycosylphosphatidylinositol-anchored avidin as a reporter protein for in vivo imaging,” Journal of Nuclear Medicine, vol. 52, no. 3, pp. 445–452, 2011. View at Publisher · View at Google Scholar · View at Scopus
  30. C. Hsieh, J. Kuo, Y. Lee, C. Chang, J. G. Gelovani, and R. Liu, “Construction of mutant TKGFP for real-time imaging of temporal dynamics of HIF-1 signal transduction activity mediated by hypoxia and reoxygenation in tumors in living mice,” Journal of Nuclear Medicine, vol. 50, no. 12, pp. 2049–2057, 2009. View at Publisher · View at Google Scholar · View at Scopus
  31. P. Brader, C. C. Riedl, Y. Woo et al., “Imaging of hypoxia-driven gene expression in an orthotopic liver tumor model,” Molecular Cancer Therapeutics, vol. 6, no. 11, pp. 2900–2908, 2007. View at Publisher · View at Google Scholar · View at Scopus
  32. F. He, X. Deng, B. Wen et al., “Noninvasive molecular imaging of hypoxia in human xenografts: comparing hypoxia-induced gene expression with endogenous and exogenous hypoxia markers,” Cancer Research, vol. 68, no. 20, pp. 8597–8606, 2008. View at Publisher · View at Google Scholar · View at Scopus
  33. S. Lehmann, D. P. Stiehl, M. Honer et al., “Longitudinal and multimodal in vivo imaging of tumor hypoxia and its downstream molecular events,” Proceedings of the National Academy of Sciences of the United States of America, vol. 106, no. 33, pp. 14004–14009, 2009. View at Publisher · View at Google Scholar · View at Scopus
  34. A. Y. Yu, M. G. Frid, L. A. Shimoda, C. M. Wiener, K. Stenmark, and G. L. Semenza, “Temporal, spatial, and oxygen-regulated expression of hypoxia-inducible factor-1 in the lung,” The American Journal of Physiology—Lung Cellular and Molecular Physiology, vol. 275, no. 4, pp. L818–L826, 1998. View at Google Scholar · View at Scopus
  35. T. Kudo, M. Ueda, Y. Kuge et al., “Imaging of HIF-1-active tumor hypoxia using a protein effectively delivered to and specifically stabilized in HIF-1-active tumor cells,” Journal of Nuclear Medicine, vol. 50, no. 6, pp. 942–949, 2009. View at Publisher · View at Google Scholar · View at Scopus
  36. M. Ueda, T. Kudo, Y. Kuge et al., “Rapid detection of hypoxia-inducible factor-1-active tumours: pretargeted imaging with a protein degrading in a mechanism similar to hypoxia-inducible factor-1α,” European Journal of Nuclear Medicine and Molecular Imaging, vol. 37, no. 8, pp. 1566–1574, 2010. View at Publisher · View at Google Scholar · View at Scopus
  37. T. Kudo, M. Ueda, H. Konishi et al., “PET imaging of hypoxia-inducible factor-1-active tumor cells with pretargeted oxygen-dependent degradable streptavidin and a novel 18F-labeled biotin derivative,” Molecular Imaging and Biology, vol. 13, no. 5, pp. 1003–1010, 2011. View at Publisher · View at Google Scholar · View at Scopus
  38. M. Ueda, T. Kudo, Y. Mutou et al., “Evaluation of [125I]IPOS as a molecular imaging probe for hypoxia-inducible factor-1-active regions in a tumor: Comparison among single-photon emission computed tomography/X-ray computed tomography imaging, autoradiography, and immunohistochemistry,” Cancer Science, vol. 102, no. 11, pp. 2090–2096, 2011. View at Publisher · View at Google Scholar · View at Scopus
  39. H. Fujii, M. Yamaguchi, K. Inoue et al., “In vivo visualization of heterogeneous intratumoral distribution of hypoxia-inducible factor-1α activity by the fusion of high-resolution SPECT and morphological imaging tests,” Journal of Biomedicine and Biotechnology, vol. 2012, Article ID 262741, 6 pages, 2012. View at Publisher · View at Google Scholar · View at Scopus
  40. M. Ueda, “Development of a method for high-contrasted nuclear medical imaging of hypoxia-inducible factor-1-active tumor by using a pretargeting approach,” Yakugaku Zasshi, vol. 132, no. 5, pp. 595–600, 2012. View at Publisher · View at Google Scholar · View at Scopus
  41. M. Ueda, K. Ogawa, A. Miyano, M. Ono, S. Kizaka-Kondoh, and H. Saji, “Development of an oxygen-sensitive degradable peptide probe for the imaging of hypoxia-inducible factor-1-active regions in tumors,” Molecular Imaging and Biology, vol. 15, no. 6, pp. 713–721, 2013. View at Publisher · View at Google Scholar
  42. H. Harada, M. Hiraoka, and S. Kizaka-Kondoh, “Antitumor effect of TAT-oxygen-dependent degradation-caspase-3 fusion protein specifically stabilized and activated in hypoxic tumor cells,” Cancer Research, vol. 62, no. 7, pp. 2013–2018, 2002. View at Google Scholar · View at Scopus
  43. S. Kizaka-Kondoh, S. Itasaka, L. Zeng et al., “Selective killing of hypoxia-inducible factor-1-active cells improves survival in a mouse model of invasive and metastatic pancreatic cancer,” Clinical Cancer Research, vol. 15, no. 10, pp. 3433–3441, 2009. View at Publisher · View at Google Scholar · View at Scopus
  44. R. Haubner, S. Maschauer, and O. Prante, “PET radiopharmaceuticals for imaging integrin expression: tracers in clinical studies and recent developments,” BioMed Research International, vol. 2014, Article ID 871609, 17 pages, 2014. View at Publisher · View at Google Scholar
  45. D. Zeng, B. M. Zeglis, J. S. Lewis, and C. J. Anderson, “The growing impact of bioorthogonal click chemistry on the development of radiopharmaceuticals,” Journal of Nuclear Medicine, vol. 54, no. 6, pp. 829–832, 2013. View at Publisher · View at Google Scholar · View at Scopus
  46. S. Balogova, J. Talbot, V. Nataf et al., “18F-Fluorodihydroxyphenylalanine vs other radiopharmaceuticals for imaging neuroendocrine tumours according to their type,” European Journal of Nuclear Medicine and Molecular Imaging, vol. 40, pp. 943–966, 2013. View at Google Scholar
  47. S. Sobhanifar, C. Aquino-Parsons, E. J. Stanbridge, and P. Olive, “Reduced expression of hypoxia-inducible factor-1α in perinecrotic regions of solid tumors,” Cancer Research, vol. 65, no. 16, pp. 7259–7266, 2005. View at Publisher · View at Google Scholar · View at Scopus
  48. X. Li, S. Carlin, M. Urano, J. Russell, C. C. Ling, and J. A. O'Donoghue, “Visualization of hypoxia in microscopic tumors by immunofluorescent microscopy,” Cancer Research, vol. 67, no. 16, pp. 7646–7653, 2007. View at Publisher · View at Google Scholar · View at Scopus
  49. J. Sato, Y. Kitagawa, Y. Yamazaki et al., “18F-fluoromisonidazole PET uptake is correlated with hypoxia-inducible factor-1a expression in oral squamous cell carcinoma,” Journal of Nuclear Medicine, vol. 54, no. 7, pp. 1060–1065, 2013. View at Publisher · View at Google Scholar · View at Scopus
  50. N. Kawai, W. Lin, W. D. Cao, D. Ogawa, K. Miyake, and R. Haba, “Correlation between F-fluoromisonidazole PET and expression of HIF-1α and VEGF in newly diagnosed and recurrent malignant gliomas,” European Journal of Nuclear Medicine and Molecular Imaging, 2014. View at Publisher · View at Google Scholar
  51. M. Hu, L. Xing, D. Mu et al., “Hypoxia imaging with 18F-fluoroerythronitroimidazole integrated PET/CT and immunohistochemical studies in non-small cell lung cancer,” Clinical Nuclear Medicine, vol. 38, no. 8, pp. 591–596, 2013. View at Publisher · View at Google Scholar · View at Scopus
  52. J. Cheng, L. Lei, J. Xu et al., “18F-fluoromisonidazole PET/CT: a potential tool for predicting primary endocrine therapy resistance in breast cancer,” Journal of Nuclear Medicine, vol. 54, no. 3, pp. 333–340, 2013. View at Publisher · View at Google Scholar · View at Scopus
  53. R. Takebayashi, K. Izuishi, Y. Yamamoto et al., “Fluorodeoxyglucose accumulation as a biological marker of hypoxic status but not glucose transport ability in gastric cancer,” Journal of Experimental and Clinical Cancer Research, vol. 32, no. 1, article 34, 2013. View at Publisher · View at Google Scholar · View at Scopus